Synlogic Announces Phenylketonuria Data Presentation at the 14th International Congress on Innate Errors of Metabolism
CAMBRIDGE, Mass., November 10, 2021 / PRNewswire / – Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced the presentation of new data from the clinical development program of the Society for Phenylketonuria (PKU) at the 14th Annual Congress of Innate Errors of Metabolism Meeting held at Sydney, Australia November 21-24, 2021.
Last minute oral presentation:
Summary # 568: Reduction of Plasma Phenylalanine Levels in Patients with Phenylketonuria with Live Bacterial Therapeutic SYNB1618.
Presenter: Dr. Jerry vockley, University of Pittsburgh and the UPMC Children’s Hospital of Pittsburgh
Session: Breaking news, Tuesday 23 Novembere, 10:45 a.m. – 11:45 a.m. Local time (AEDT) / 7:45 p.m. – 8:45 p.m. (EDT)
Summary # 569: Increased Phe Lowering Potential with SYNB1934, a Living Biotherapeutic with Improved PAL Variant. Presenter: Dr. Marja puurunen, Synlogic
Summary # 278: Development of an optimized and improved live bacterial therapeutic agent for the degradation of phenylalanine, SYNB1934, for the treatment of phenylketonuria. Presenter: Catherine monahan, Synlogic
Summary # 474: Characterization of dietary protein intake in PKU patients. Presenter: Dr Mesaki K. Ndugga-Kabuye, Synlogic
In addition to presentations on the PKU program, preclinical data for SYNB1353, an experimental synthetic biotic drug consuming methionine for the treatment of homocystinuria, will also be presented.
Learn more about Synlogic’s programs and pipeline by visiting https://www.synlogictx.com/.
Synlogic ™ brings the transformative potential of synthetic biology to medicine. With a leading synthetic biology platform that leverages a reproducible and modular approach to microbial engineering, Synlogic designs synthetic biotic drugs that target the underlying biology validated to treat disease in new ways. Synlogic’s proprietary pipeline includes synthetic biotics for the treatment of metabolic disorders including phenylketonuria (PKU) and enteric hyperoxaluria. The company is also in the process of building a portfolio of assets that can be the subject of partnerships in immunology and oncology.
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for the safe harbor purposes of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in This press release regarding strategy, future operations, clinical development plans, future financial condition, future revenues, projected expenses, outlook, plans and objectives of management are forward-looking statements. In addition, when or if they are used in this press release, the words “may”, “could”, “should”, “anticipate”, “believe”, “estimate”, “‘wait”, “have the ‘intention to’, ‘plan’, ‘predict’ and similar expressions and variations thereof, with respect to Synlogic, may identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements regarding the potential of Synlogic’s platform to develop therapies to treat a wide range of diseases, including: cancer, inborn errors of metabolism and disorders inflammatory and immune systems; our expectations as to the adequacy of our existing cash balance; the future clinical development of synthetic biotic drugs; the approach adopted by Synlogic to discover and develop new therapies using synthetic biology; and the anticipated timing of Synlogic’s clinical trials on SYNB1618 or SYNB1934, and the availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statement due to various factors, including: uncertainties inherent in the clinical and preclinical development process; Synlogic’s ability to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as the risks identified under the heading “Risk Factors” in the documents filed by Synlogic with the SEC. The forward-looking statements contained in this press release reflect Synlogic’s current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause a change of opinion. However, although Synlogic may choose to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be taken as representing the views of Synlogic as of any date subsequent to the date hereof.
View original content: https://www.prnewswire.com/news-releases/synlogic-announces-presentation-of-phenylketonuria-data-at-14th-international-congress-of-inborn-errors-of-metabolism-meeting – 301420438.html
SOURCE Synlogic, Inc.